The basics of Monoclonal Antibody Development and Antibody Production

1. The basics of Monoclonal Antibody Development and Antibody Production Antibody Production Services Genosphere Biotechnologies offers complete polyclonal antibody production services packages, including peptide or protein antigen synthesis, choice of hosts immunization, antibody purification, and quality control analyses. Our polyclonal antibody production services are designed to meet a variety of experimental requirements. For example, depending of the planned experiments, antisera or purified antibodies can be provided. Multiple purification methods are available, including protein A and antigen affinity purification. Purification of the antisera is used to enrich the antibody activities. Genosphere Biotechnologies has long experience in successful polyclonal antibody development and guarantees an ELISA titer above 1:100,000. We offer multiple packages that can fit various customer needs. Our featured development packages can guarantee the delivery of fully-validated rabbit, guinea pig, rat, or mouse polyclonal antibodies within 70 days. Our polyclonal antibody development services are based on years of process optimization and a strong reputation for reliable antibody production services. We have been a preferred partner to various institutions worldwide for antibody development and antibody production services for over 25 years. Antibody Production Services Highlights

2. • Guaranteed ELISA titer >1:50,000. • Proprietary peptide design tools and high-efficiency conjugation ensure a >95% success rate of peptide immunization. • Integrated antigen preparation: from gene synthesis to protein antigen expression and purification Monoclonal Antibody Development Mouse monoclonal antibodies have broad applications as therapeutics, diagnostic tools, and research reagents. Genosphere Biotechnologies provides comprehensive mouse monoclonal antibody development services based on our well-established hybridoma platform. We provide complete support for all steps of mouse monoclonal antibody development, from antigen preparation to animal immunization, fusion and screening, subcloning, and antibody production, which allows the identification of clones with the desirable qualities. We provide free consultation for target antigen design and expression, and our experienced project managers and scientists will support you directly throughout the process. Since the Nobel-winning prize pioneer work in 1975 on hybridoma technique the monoclonal antibody development and manufacturing process has been refined. In a nutshell, the generation of hybridomas involves immunising mice against a specific epitope on an antigen and obtaining the B-lymphocytes from the spleen of the animals. The B-lymphocytes are then fused with an immortal myeloma cell line lacking the hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene. These hybridoma cells are further cultured in vitro in selective medium (i.e. hypoxanthine-aminopterin-thymidine +) where only the hybridomas -that is the fusion between the primary B-lymphocytes and myeloma cells- can survive as they have inherited immortality from the myeloma cells and selective- resistance from the primary B-lymphocytes. The initial culture of hybridomas contains a pool of antibodies derived from many different primary B-lymphocyte clones, each secreting its own individual specific antibody into the culture medium hence, at this point, the antibodies are still polyclonals. Each individual clone is separated by dilution and the supernatant screened for the targeted specific antibody. These cells are then characterized and cloned to allow production over time. Genosphere Biotechnologies Address: 52 rue du Moulin de Pierre,92140 Clamart,FRANCE Tel: +33 - 142 717 021 Fax: +33 - 142 717 023 Email: info@genosphere-biotech.com Website: https://www.genosphere-biotech.com/